The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Challenge, 2014Mitochondrial Homeostasis and LRRK2 Parkinsonism: Novel Neuroprotection Targets
Objective/Rationale:
The genes related to familial forms of Parkinson’s disease (PD) have been associated with alterations of normal mitochondrial integrity and function. Little is known... -
Rapid Response Innovation Awards, 2014Disease-modifying Potential of Nortriptyline in Parkinson’s Disease
Objective/Rationale:
Aggregation of the protein alpha-synuclein is toxic to dopamine neurons. Therefore, a compound that reduces or clears this protein could be a viable therapeutic option... -
Rapid Response Innovation Awards, 2014Reduced Habitual Intrusions: An Early Marker of Parkinson's Disease?
Study Rationale:
Parkinson's disease is characterized by the loss of a neurotransmitter called dopamine in a part of the brain called the basal ganglia. Parts of this region are... -
Improved Neuromodulation Approaches, 2014Responsive, Closed-Loop Approach to Treat Freezing of Gait in Parkinson’s Disease
Study Rationale:
Levodopa-resistant posture, gait and freezing symptoms are among the most disabling and difficult to treat in people with Parkinson’s disease (PD). Recent findings... -
Target Validation, 2014Seeking Neuroprotection via a Novel Complex-1 Chaperone
Objective/Rationale:
Mitochondria are the powerplants of the cell, and decades of evidence suggest that they may be defective in the brains of people with Parkinson’s. The overall goal of... -
Therapeutic Pipeline Program, 2014Evaluation of the Oligomer Modulator anle138b in a Seeding-based Model of Parkinson’s Disease
Objective/Rationale:
Mounting evidence indicates a crucial role of pathological aggregates of the protein alpha-synuclein in Parkinson’s disease (PD). Small aggregates termed oligomers...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.